Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2016

01-05-2016 | Original Article

Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials

Authors: M. A. Amiche, J. M. Albaum, M. Tadrous, P. Pechlivanoglou, L. E. Lévesque, J. D. Adachi, S. M. Cadarette

Published in: Osteoporosis International | Issue 5/2016

Login to get access

Abstract

Summary

Little data exist on the frequency of fracture among oral glucocorticoid users. We examined the effect of oral glucocorticoids on fracture incidence using data from randomized controlled trials. Patients starting glucocorticoids had a higher probability of fracture and decline in bone mineral density compared to chronic glucocorticoid users.

Introduction

Oral glucocorticoids (GCs) are the leading cause of secondary osteoporosis. However, there have been few studies that quantify the rate of fracture among GC users. We sought to provide a pooled estimate of fracture risk from randomized controlled trials (RCTs) of GC-treated patients.

Methods

We updated a MEDLINE search published by the American College of Rheumatology through to March 2015 and identified RCTs of osteoporosis therapies that reported fracture and bone mineral density (BMD) among oral GC users. We restricted the analysis to placebo or control arms. RCT arms were stratified by GC exposure at enrolment to GC initiators (≤6 months) and chronic GC users (>6 months). Bayesian meta-regression was used to estimate the annual probability of vertebral fracture (primary), non-vertebral fracture and percentage change in lumbar spine and femoral neck BMD.

Results

The annual incidence of vertebral and non-vertebral fracture was 5.1 % (95 % CrI = 2.8–8.2) and 2.5 % (95 % CrI = 1.2–-4.2) among GC initiators, and 3.2 % (95 % CrI = 1.8–5.0) and 3.0 % (95 % CrI = 0.8–5.9) among chronic GC users. Our meta-regression identified a non-significant effect of group-level variables (mean age, mean BMD, mean GC daily dose, patients with previous vertebral fractures, proportion of women and adjuvant used) on vertebral fracture rate.

Conclusion

Our study found higher vertebral fracture incidence among GC initiators, yet a relative decline in fracture incidence with longer exposure. Our findings suggest that fracture incidence among oral GC users may be more common than previously estimated. Optimizing GC-induced osteoporosis management during early exposure to GC is essential to prevent fractures.
Appendix
Available only for authorised users
Literature
1.
Van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129–137CrossRefPubMed
2.
Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef
3.
Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMed
4.
Devogelaer J-P, Goemaere S, Boonen S et al (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian bone club. Osteoporos Int 17:8–19CrossRefPubMed
5.
Gourlay M, Franceschini N, Sheyn Y (2007) Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 26:144–153CrossRefPubMed
6.
Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873CrossRefPubMedPubMedCentral
7.
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276CrossRefPubMed
8.
de Nijs RNJ, Jacobs JWG, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. NEJM 355:675–684CrossRefPubMed
9.
Ismail AA, Pye SR, Cockerill WC et al (2002) Incidence of limb fracture across Europe: results from the European prospective osteoporosis study (Epos). Osteoporos Int 13:565–571CrossRefPubMed
10.
Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRefPubMed
11.
Jenkins EA, Walker-Bone KE, Wood A et al (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 28:152–156CrossRefPubMed
12.
Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C (1999) Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rhum Engl Ed 66:214–219PubMed
13.
Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318CrossRefPubMed
14.
Roux C, Oriente P, Laan R et al (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos study group. J Clin Endocrinol Metab 83:1128–1133CrossRefPubMed
15.
van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed
16.
Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899CrossRefPubMed
17.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328CrossRefPubMed
18.
den Uyl D, Bultink IE, Lems WF (2011) Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 13:233–240CrossRef
19.
Dore RK (2013) Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Prefer Adherence 7:435–446CrossRefPubMedPubMedCentral
20.
Panday K, Gona A, Humphrey MB (2014) Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Disord 6:185–202CrossRef
21.
Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259CrossRefPubMed
22.
Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512–1526CrossRefPubMed
23.
Homik JE, Cranney A, Shea B et al (1999) A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 26:1148–1157PubMed
24.
Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98–109CrossRefPubMed
25.
Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59–70CrossRefPubMed
26.
Sutton AJ, Abrams KR (2001) Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10:277–303CrossRefPubMed
27.
Dias S, Welton NJ, Sutton AJ, Ades AE (2013) Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Mak 33:657–670CrossRef
28.
29.
Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol 41:818–827CrossRefPubMedPubMedCentral
30.
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRefPubMed
31.
Kalpakcioglu BB, Engelke K, Genant HK (2011) Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone 48:1221–1231CrossRefPubMed
32.
Rüegsegger P, Medici TC, Anliker M (1983) Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25:615–620CrossRefPubMed
33.
Albaum JM, Lévesque LE, Gershon AS, Liu G, Cadarette SM (2015) Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012. Osteoporos Int 26:2845–2852CrossRefPubMed
34.
Majumdar SR, Lix LM, Morin SN et al (2013) The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol 40:1736–1741CrossRefPubMed
35.
LoCascio V, Bonucci E, Imbimbo B et al (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51CrossRefPubMed
36.
Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (horizon): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263CrossRefPubMed
37.
Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63–70CrossRefPubMed
38.
Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J (2004) Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol 34:717–721CrossRefPubMed
39.
Dias S, Sutton AJ, Welton NJ, Ades AE (2013) Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment. Med Decis Mak 33:618–640CrossRef
40.
van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21:589–624CrossRefPubMed
Metadata
Title
Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials
Authors
M. A. Amiche
J. M. Albaum
M. Tadrous
P. Pechlivanoglou
L. E. Lévesque
J. D. Adachi
S. M. Cadarette
Publication date
01-05-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 5/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3455-9

Other articles of this Issue 5/2016

Osteoporosis International 5/2016 Go to the issue

Original Article

Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial

Original Article

Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus

Original Article

Are bone turnover markers associated with volumetric bone density, size, and strength in older men and women? The AGES–Reykjavik study

Original Article

Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study

Original Article

IL-4 administration exerts preventive effects via suppression of underlying inflammation and TNF-α-induced apoptosis in steroid-induced osteonecrosis

Original Article

Association of osteoporosis and bone medication with the periodontal condition in elderly women